drug
ifezuntirgene inilparvovec
Phase 2updated 6mo agoby UniQure NV
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(4)
- FDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’The FDA has accepted uniQure’s priority review and application for its gene therapy treatment for Huntington’s disease.fiercebiotech · 17d ago
- UniQure snags May Day decision date for Huntington’s gene therapy after arduous yearAfter a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy…biospace · 17d ago
- Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.biospace · 27d ago
- UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 yearsThe results are nevertheless “unprecedented,” UniQure executives said on an investor call Tuesday, emphasizing that the updated natural history database used as the control group for the Phase 1/2…biospace · 1mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that